Lab operations experts dive deep into pitfalls of manual sample and consent tracking and the need for purpose-driven automated solutions in a fast-paced, complex and unpredictable development landscape
RESEARCH TRIANGLE PARK, N.C.— BioFortis, a company of leading global clinical trial laboratory services organization Q2 Solutions, will share insights into how clinical trial sponsors can effectively digitize sample and consent tracking and management to meet the increasing demands of today’s drug development landscape, at the 14th annual SCOPE Summit for clinical operations executives in Orlando, FL, being held from February 6-9.
As part of SCOPE’s key program focus on “Biomarker Technology and Innovation”, on Tuesday, February 7, BioFortis General Manager David Kaye will lead a presentation titled, “Clinical Trial and Consent Management: Too Important to Leave to Chance” at 12:10 pm EST. A discussion vital for trial sponsors looking to enhance trial efficiencies with quality and safety in mind, David will highlight how clinical trial sample and consent tracking (CTST) software can transform the way pharmaceutical companies oversee specimen management with efficiency and clear workflow visibility, shifting away from historical “pen and paper” manual methods for data collection.
In a demanding and competitive landscape, sponsors are in need of heightened efficiencies, reducing timelines and cost, to effectively continue drug development. Depending on the size of modern trials, sponsors may be collecting and storing millions of specimen samples and related datasets per trial. By factoring in consent tracking needs, the management process becomes that much more arduous. Manual data collection can increase costly inefficiencies and risk of human error to the complex process, making an integrated and automated approach to end-to-end sample management and consent tracking critical.
Specifically, SCOPE 2023 attendees will take away tangible insights on how Q2 Solutions’ Labmatrix® software allows sponsors to use a single, web-based platform hub for a comprehensive, holistic view of sample data progress and tracking in real-time and how this software solution can help sponsors reduce error risk.
Key benefits of a scalable CTST solution that will be highlighted in the discussion, include:
- Ability for sponsors and study teams to closely monitor in-study samples and consent data when needed, regardless of site, country or vendor partner. This helps in:
- Providing key oversight of sample verification and expiry.
- Enriching in-study analyses to quickly spot and catch areas needing adjustments and closer attention, such as availability, location, processing and shipping status.
- Improving regulatory sample and data reviews.
- Track samples throughout their full lifecycle, from sites to labs to biorepositories and more.
- Reduce manual data reconciliation and improve data harmonization via fuzzy matching functionality, allowing for better handling of larger audit logs and robust data indexing.
- Access to eClinical data in near real-time.
- Efficient oversight of consent tracking to support collection compliance and use for future trials.
“We are in the era of big data, where sponsors may be overseeing millions of patient samples and related consent activities in any given trial program,” said David. “As samples are the lifeline of many clinical trials, it’s vital that sponsors transform how sample and consent data is collected and monitored throughout the entire trial lifecycle. An integrated CTST system allows for a bird’s eye view of tracking, where sponsors can better anticipate full lifecycle flow and make changes quicker, given real-time monitoring of data movement.”
Along with participating in this meaningful dialogue with industry stakeholders, BioFortis is also a corporate sponsor for SCOPE 2023. Key team members will be available at booth #913 (located on the right side of the exhibitor hall entrance) to learn more about your specific needs in sample management and improving efficiencies.
About Q2 Solutions
Q2 Solutions is a leading global clinical trial laboratory services organization providing comprehensive testing, project management, supply chain, biorepository and specimen management, and clinical trial sample and consent tracking solutions. Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients. We focus our innovative solutions and scientific expertise on ADME, bioanalytical, genomics, immunoassays testing, vaccines and central laboratory services, including flow cytometry, anatomic pathology, molecular and companion diagnostics, and decentralized clinical trials while providing meticulous regional and global clinical trial implementation support and high-quality data delivery. Our Translational Science and Innovation Laboratory (TSAIL) provides access to a broad range of resources, including a multidisciplinary approach to early-stage human biomarker discovery and clinical sample testing to help accelerate drug development.
At Q2 Solutions, our work is rooted in research, grounded in collaboration, and guided by our passion to turn the hope of patients and caregivers around the world into the help they need.
To learn more, visit q2labsolutions.com/scope-2023.
